repair of damaged DNA (Campalans et al., 2013) . The mechanism of PARP-1 in doxorubicin-induced apoptosis and/or DNA repair also remains unknown. Doxorubicin (Adriamycin, ADR) is one of the most widely used anticancer agents. It eliminates tumor cells by inhibiting DNA replication and interrupting mitosis though covalent DNA-binding (Zaremba et al., 2010) . Recently, it was reported that ADR can increase the expression of PAR (an active product of PARP-1) and promote damaged DNA repair and induce chemotherapy resistance (Munoz-Gamez et al., 2005) . However, the mechanisms for ADR's roles remain unexplored. In this study, we found a novel mechanism that the increased PARP-1 activity by ADR was directly mediated through the down-regulation of Kif4A, and thus induced cell apoptosis in breast cancer cells.
MATERIAL AND METHODS

Cell culture
Breast cancer cell lines MCF-7 (with wild-type p53) and MDA-MB-231 (with mutant p53) were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Shanghai, China. The cells were cultured in high glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, 100 U/ml streptomycin, and 2 mmol/L L-glutamine, at 37°C in a humidified 5% CO 2 atmosphere.
Cell treatment
Cells were plated into 35 mm dishes 3  10 5 ; MDA-MB-231, 5  10 5 ), on the next day treated with 0.05, 0.1, 0.5, 1.0, and 2.0 mol/L ADR in 3 replicates for 24 h, followed by 12 h of recovery. Cells were lysed with 1 cell lysis buffer for protein analysis. The control cells were handled exactly same except ADR treatment. Cells treated with 1 M ADR for 24 h and recovered for 6, 12, 24, and 48 h were collected for Western blot analysis. The HA-Kif4A plasmid was transfected into cells by using Lipofectamine
2000
. The 24 h after transfection, the cells were treated with 1 M ADR for 24 h, followed by 24 h recovery. Cells transfected with HA-pcDNA3.0 plasmid but without ADR treatment were used as a control. The cells were collected to detect the expression levels of related proteins by Western blot and to measure cell apoptosis by flow cytometry (FCM). Cells were plated and treated with 2.5, 5, 10, and 20 M PARP-1 inhibitor (3-Aminobenzamide, 3-ABA, dissolved in DMSO) for 24 h, followed by 12 h of recovery. Cells were collected to detect the expression of Kif4A and PARP-1 proteins by Western blot. Cells without 3-ABA treatment were used as a control. The cells were treated with 5 M 3-ABA and 1 M ADR for 24 h, followed by 12 h of recovery, then collected to measure cell apoptosis by FCM.
Western blot analysis
Cells were washed with PBS and lysed in 100 l lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton-X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , and 1 g/ml leupeptin) for 10 min on ice. The supernatant was collected by centrifugation and mixed with sample buffer. Proteins were resolved by SDS-PAGE (8% gel) and transferred onto poly-vinylidene difluoride (PVDF) membrane. The blot was blocked with 5% (w/v) non-fat milk in PBS containing 0.1% Tween for 1 h, washed with PBST, incubated overnight with antibodies against Kif4A (Santa Cruz Technology, USA), PARP-1 (Cell Signaling Technology, USA), PAR (SAB, USA) and -tubulin (Sigma, USA), and incubated for 2 h with appropriate secondary antibody. Protein bands were visualized by ECL-plus (Amersham Biosciences, USA), and pictures were taken with the Chemi-Doc XPS imaging system.
Detection of cell apoptosis
The treated cells were washed twice with cold PBS, then harvested and resuspended in 1 binding buffer. The 5 l FITC Annexin V and 5 l PI (Propidium Iodide) were added to cell suspension and incubated for 10 min at room temperature in the dark, then 400 l 1 binding buffer was added to each tube for FCM analysis (Becton Dickinson, USA) within 1 h.
Statistical analysis
The bands from Western blotting were quantified by Image-Pro Plus 6.0. Results were presented as mean  standard deviation (SD). The t-test was performed using the Statistical Package for Social Science (SPSS for Windows package release 17.0). P < 0.05 was considered statistically significant. *P < 0.05; **P < 0.01.
RESULTS
ADR treatment induces Kif4A down-regulation and PARP-1 activation Kif4A has been used to examine the status of DNA damage and DNA repair. It has been shown in many different cells that infringing DNA damage activates PARP-1. The effect of DNA damaging agent ADR on PARP-1 activity remains unknown. We hypothesized that the activation of PARP-1 induced by ADR may counteract the ADR-induced cytotxicity by promoting DNA repair, and PARP-1 activation was regulated by Kif4A. In Fig. 1 , we used different concentrations of ADR to treat MCF-7 and MDA-MB-231 cells for 24 h, and found that the expression levels of Kif4A were gradually decreased in a dose-dependent manner (Figs. 1A and 1C) . Moreover, ADR could induce PARP-1 activation in a dose-dependent manner (Figs. 1A and 1C) . While the expression of full-length PARP-1 was not changed, smaller cleaved bands of PARP-1 were observed. Furthermore, we also treated MCF-7 and MDA-MB-231 cells with 1 M ADR for 24 h and recovered the cells for 6, 12, 24, and 48 h. Our results showed that the expression of Kif4A was decreased gradually in a time-dependent manner, while the expression of PAR was increased gradually with longer recovery time (Figs. 2A and 2C) . The expression of full-length PARP-1 was not significantly changed at all recovery time points.
Kif4A expression is not affected by PARP-1 inhibitor PARP-1 inhibitor has a potential clinical application. One of PARP-1 inhibitors, 3-ABA, can significantly decrease the expression of PAR transfer enzymes and prevent ADR-induced PARP-1 activation. To investigate whether PARP-1 inhibitor affects the expression of Kif4A, we treated MCF-7 and MDA-MB-231 cells with 2.5, 5, 10, and 20 M 3-ABA 24 h, followed by 12 h of recovery. As shown in Fig. 3, 3 -ABA inhibited the expression of PAR but did not affect the expression of Kif4A and the fulllength PARP-1.
Kif4A inhibits PARP-1 activation
It has been reported that Kif4A promotes neuronal survival through suppressing PARP-1 activity (Midorikawa et al., 2006) . However, the relationship between Kif4A and PARP-1 in cancer has not been investigated. In this study, we transfected HA-Kif4A into MCF-7 cells using Lipofectamine  2000. After 24 h, the cells were treated with 1 M ADR for 24 h, followed by 12 h of recovery. We also verified the role of Kif4A in p53-deficient breast cancer cell line, MDA-MB-231. PARP-1 activation and PAR expression were significantly inhibited by Kif4A overexpression, as compared with those in the control and HA-pcDNA groups (Figs. 
Co-treatment of MCF-7 and MDA-MB-231 cells with doxorubicin and 3-ABA potentiates cell apoptosis
We further investigated whether the changes of Kif4A expression and PARP-1 activation induced by ADR might be directly related to the cytotoxicity. MCF-7 and MDA-MB-231 cells were 5A(b) and 5A(c)], respectively, compared with the control group 3.85  0.26% [ Fig. 5A (a)] (P < 0.05). The co-treatment of 3-ABA and ADR led to further increase in apoptosis rate at 10.24  0.81% [ Fig. 5A(d) ], which was significantly higher than that in 3-ABA or 
DISCUSSION
ADR is an widely used anticancer agent with broad spectrum of activities involving DNA intercalation, free-radical formation, covalent DNA binding, inhibition of the topoisomerase II, and DNA strand breakage (Hydock et al., 2012; Zaremba et al., 2010) . Extensive studies have contributed to understanding ADR chemoresistance (Xu et al., 2013) . Recent studies demonstrated that permeability glycoprotein (P-gp) (Sun et al., 2012; Zheng et al., 2010) , breast cancer resistance protein (BCRP) (Sukowati et al., 2012) , multidrug resistance-associated proteins (MRPs) (Villar et al., 2012) , breast cancer associated 1 (BRCA1), and PARP-1 may all play important roles in chemotherapy resistance (Alli et al., 2011) . PARP-1 may be activated by ADR for DNA repair (Farmer et al., 2005; Javle and Curtin, 2011) . PARP-1 has caused much attention because PARP-1 inhibitors have been used as new therapeutic drugs for different cancers. Studies have shown that compare with ADR, PARP-1 inhibitors are more effective to BRCA1 mutant breast cancer (Ibragimova and Cairns, 2011) and/or triple-negative breast cancer (Oonk et al., 2012) , suggesting a correlation between ADR resistance and PARP-1 activation. It has been demonstrated that both PARP and BRCA regulate the pathways of DNA repair. Due to the accumulation of mutations induced by error-prone DNA repair, breast cancers mostly develop in the setting of BRCA deficiency. A series of recent clinical trials have tested the application of PARP inhibition as a therapeutic strategy to target BRCA-deficient tumors (Annunziata and Bates, 2010) . PARP-1 activity can also be a biomarker of DNA repair deficiency in breast cancer (Jacot et al., 2013) . It has been reported that Kif4A regulates middle-spindle formation by interacting with the protein regulator of cytokinesis 1, PRC1 (Shrestha et al., 2012) . Kif4A is a candidate molecule that may play critical roles in DNA damage response and/or DNA repair pathways (Wu et al., 2008) . Midorikawa et al. (2006) demonstrated that Kif4A promotes neuron apoptosis by suppressing PARP-1 activity. These findings prompt us to investigate the impact of ADR on Kif4A and PARP-1 as a potential novel mechanism of resistance mechanism. Furthermore, it has been reported that PARP inhibition may represent a novel way of selectively targeting p53-deficient breast cancer cells (Munoz-Gamez et al., 2005) . To further verify our hypothesis, we used two breast cancer cells MCF-7 (with wild-type p53) and MDA-MB-231 (p53-deficient) to study whether p53 play a role in PARP-1 inhibition-induced apoptosis. The results showed that PARP inhibition was more selective in p53-deficient MDA-MB-231 cells compared with wild-type p53 MCF-7 cells. In this study, we found that in two of breast cancer cell lines: (1) ADR treatment inhibited the expression Kif4A but activated PARP-1; (2) More directly, ectopic expression of Kif4A inhibited PARP-1 activity, decreased DNA-repair function, and induced cell apoptosis; (3) ADR treatment induced cell apoptosis by inhibiting Kif4A expression along with increasing the PARP-1 activity to enhance the effect on DNA-damage. We also found that the combined treatment of ADR and PARP-1 inhibitor further enlarged the rate of apoptosis compared with ADR treatment alone, suggesting a role of PARP-1 in ADR resistance. Furthermore, we showed that ADR did not affect exogenous Kif4A; ADR might mainly regulate Kif4A in the process of transcription. Our findings may help further understand the mechanisms of PARP-1-mediated ADR resistance.
Therefore, a clear understanding of the relationships among ADR, Kif4A, PARP-1, BRCA1 and BRCA2 in the future may help to reveal the mechanism of ADR resistance in some cancer cells.
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